Medicine Information

Eposis

Name: Eposis
Brand: Eposis
Rating: 4.5 (117 reviews)

Injection2000 IUHematopoietic Agent, Erythropoiesis-Stimulating Agent (ESA)ATC: B03XA01

Generic Name

Epoetin Alfa 2000 IU Injection

Manufacturer

Square Pharmaceuticals Ltd.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
eposis 2000 iu injection	৳ 1,028.08	N/A

Description

Overview of the medicine

Eposis 2000 IU Injection contains Epoetin Alfa, a recombinant human erythropoietin, which stimulates the production of red blood cells in the bone marrow. It is primarily used to treat anemia associated with chronic kidney disease, chemotherapy, and certain surgical procedures.

Uses & Indications

Anemia of chronic kidney disease (CKD) in adults and children on dialysis and not on dialysis.

Anemia in cancer patients receiving myelosuppressive chemotherapy.

Anemia in zidovudine-treated HIV-infected patients.

Reduction of allogeneic red blood cell transfusions in surgery patients.

Dosage

Adults

Dosage varies significantly based on indication, patient weight, and response. Typically initiated at 50-150 IU/kg 3 times a week, adjusted to maintain target hemoglobin levels. For CKD, often 10,000 IU once weekly or 3,000 IU 3 times weekly.

Elderly

No specific dose adjustment generally required, but close monitoring is advised due to potential comorbidities.

Renal_impairment

Used to treat anemia in CKD patients. Dosage is adjusted based on hemoglobin response.

How to Take

Eposis 2000 IU Injection can be administered either intravenously (into a vein) or subcutaneously (under the skin). The choice of route depends on the patient's condition and the specific indication. It should be prepared and administered by a healthcare professional.

Mechanism of Action

Epoetin alfa binds to specific erythropoietin receptors on erythroid progenitor cells in the bone marrow, stimulating their proliferation, differentiation, and maturation into mature red blood cells. This process is known as erythropoiesis.

Pharmacokinetics

Onset

Reticulocyte count increases within 10 days, hemoglobin response within 2-6 weeks.

Excretion

Primarily renal, but very little intact drug is excreted.

Half life

IV: 4-13 hours; SC: 13-24 hours.

Absorption

Administered subcutaneously or intravenously. Subcutaneous administration results in slower absorption and lower peak concentrations compared to intravenous. Bioavailability for SC is 30-40%.

Metabolism

Primarily hepatic degradation.

Side Effects

Contraindications

Uncontrolled hypertension.
Known hypersensitivity to Epoetin alfa or any component of the formulation.
Patients with pure red cell aplasia (PRCA) that began after treatment with Epoetin alfa or other erythropoietin protein drugs.

Drug Interactions

Iron Supplements

Concurrent iron supplementation is almost always necessary to ensure an adequate response to Epoetin alfa, as erythropoiesis requires iron. Monitor iron stores regularly.

Storage

Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Do not shake.

Overdose

Overdose can lead to polycythemia (abnormally high red blood cell count), which may necessitate phlebotomy to reduce blood viscosity. Symptomatic and supportive treatment is recommended.

Pregnancy & Lactation

Pregnancy Category C. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown whether Epoetin alfa is excreted in human milk; use with caution in nursing mothers.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

1 x 2000 IU pre-filled syringe1 x 2000 IU vial

Shelf Life

Typically 24-36 months when stored as recommended. Refer to the specific product packaging for exact shelf life.

Availability

Available in hospitals and pharmacies with a prescription.

Approval Status

Approved by major regulatory bodies (e.g., FDA, EMA, DGDA)

Patent Status

Patents for original Epoetin alfa have largely expired, leading to biosimilar availability.

WHO Essential Medicine

Yes

Clinical Trials

Epoetin alfa has undergone extensive clinical trials supporting its efficacy and safety in various indications. Ongoing research includes studies on long-term outcomes, different dosing regimens, and biosimilar development.

Lab Monitoring

Hemoglobin and hematocrit levels (at least weekly initially, then regularly)
Iron status (serum ferritin, transferrin saturation)
Blood pressure monitoring
Renal function (BUN, creatinine)
Electrolytes

Doctor Notes

Closely monitor hemoglobin levels to avoid exceeding target ranges (e.g., 10-12 g/dL), as higher levels are associated with increased risks.
Ensure adequate iron stores are maintained through supplementation if needed.
Regularly monitor blood pressure and manage hypertension effectively.
Educate patients on symptoms of serious adverse events, including thrombosis and PRCA.

Patient Guidelines

Do not shake the vial.
Do not reuse needles or syringes.
Report any signs of blood clot, such as pain or swelling in limbs.
Monitor blood pressure regularly.
Attend all scheduled appointments for blood tests and dose adjustments.

Missed Dose Advice

If a dose is missed, administer it as soon as remembered. However, if it is almost time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to catch up. Consult your doctor or healthcare provider for specific advice.

Driving Precautions

Epoetin alfa can sometimes cause dizziness or seizures. Patients should be cautious when driving or operating machinery until they know how the medicine affects them.